Oncolytics Biotech (TSE:ONC) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Oncolytics Biotech Inc. (TSE:ONC) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$11.65 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.

Oncolytics Biotech Stock Down 1.3%

The stock has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The firm’s 50-day simple moving average is C$14.90 and its two-hundred day simple moving average is C$11.65.

Oncolytics Biotech (TSE:ONC) last announced its earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.